$GMAB.CO (Genmab A/S) šš¢š«š¬š š§š¢š§š š¦šØš§šš”š¬ š«šš¬š®š„šš¬ š¢š§ šššš!
Dear investors,
šššØš®š:
Genmab A/S is a biotechnology company based in Denmark, focusing on the development of antibody therapeutics for cancer treatment.
We have great revenue growth, a proposed acquisition of $MR, and many other good things for investors.
ššš² šš¢š š®š«šš¬ January - September 2025:
- revenue: 2,66bn USD - an increase from 2,2bn USD
- operating profit of 1bn vs. 667mil USD last year
šš®šš„šØšØš¤
Genmab is maintaining its 2025 financial guidance published August 7, 2025.
The financials look good. 7 billion in assets compared to 1.2 billion in liabilities and 1.7 billion in cash and equivalents.
I won't lie, I'm no expert in the field, but what the company is showing in terms of decisions and financial growth - I'm satisfied and want to learn more about it. My exposure is still small, but if I get more confidence in this, there is a probability of increasing my stake.
source:
ir.genmab.com... Show More
